The Maryland-based respiratory care device specialists developed its system for non-invasive application in neonatal, pediatric patients, as well as for adults.
And the delivery device has also been validated by Australian-based company Ikaria.
A spokesperson for Valpotherm said their aim for the Precision Flow is to be “easy for clinicians to operate but comprehensive in terms of safety and performance features.”
Bill Niland, chairman and chief business development officer at Vapotherm said: "Precision Flow is now compatible with the INOMAX DS and DSIR drug-delivery systems which provides clinicians with the ability to administer inhaled nitric oxide without the risks of more invasive methods like mechanical ventilation and pressure based therapies.”